COM:ENLIVENTHERAPEUTICS
Enlivex Therapeutics Ltd.
- Stock
Last Close
25.41
22/11 21:00
Market Cap
1.08B
Beta: -
Volume Today
254.16K
Avg: -
Preview
Full access to financials is available to subscribers only. Please support our work and get full access to all features. You can cancel anytime. If you'd like a demo, free trial or have any questions, please checkout the help page
Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | ||
|---|---|---|---|---|---|---|---|
average inventory | |||||||
average payables | 1.28M - | 1.23M 3.90% | 1.66M 35.00% | 2.98M 79.00% | 1.99M 33.38% | ||
average receivables | |||||||
book value per share | -2.79 - | 3.06 209.88% | -0.49 116.13% | -1.04 111.22% | -2.92 180.07% | 6.92 336.71% | |
capex per share | -0.01 - | -0.01 24.34% | -0.00 58.57% | -0.02 400.97% | -0.00 82.00% | ||
capex to depreciation | -4.24 - | -10.24 141.48% | -1.66 83.79% | -2.85 71.39% | -0.50 82.38% | ||
capex to operating cash flow | 0.01 - | 0.05 744.62% | 0.01 81.53% | 0.02 91.13% | 0.00 87.25% | ||
capex to revenue | |||||||
cash per share | 0.78 - | 3.06 291.59% | 3.17 3.63% | 2.68 15.60% | 2.87 7.34% | 7.12 147.89% | |
days of inventory on hand | |||||||
days payables outstanding | 653.80 - | ||||||
days sales outstanding | |||||||
debt to assets | 0.00 - | 0.00 75.04% | 0.00 176.38% | 0.00 68.22% | |||
debt to equity | -0.01 - | -0.00 28.31% | -0.00 13.40% | 0.00 132.40% | |||
dividend yield | |||||||
earnings yield | -0.02 - | -0.04 106.96% | -0.01 87.39% | -0.07 1,179.30% | -0.09 31.36% | -0.15 65.77% | |
enterprise value | 559.25M - | 561.70M 0.44% | 3.49B 522.18% | 260.04M 92.56% | 354.85M 36.46% | 392.10M 10.50% | |
enterprise value over ebitda | -49.33 - | -23.97 51.40% | -376.87 1,472.05% | -10.55 97.20% | -9.20 12.81% | -4.71 48.79% | |
ev to operating cash flow | -63.72 - | -25.68 59.70% | -409.75 1,495.89% | -13.59 96.68% | -11.06 18.60% | -6.40 42.15% | |
ev to sales | |||||||
free cash flow per share | -0.93 - | -2.33 150.85% | -0.22 90.62% | -0.47 114.96% | -1.24 164.47% | -1.73 38.95% | |
free cash flow yield | -0.02 - | -0.04 150.85% | -0.00 93.62% | -0.05 2,006.62% | -0.08 45.49% | -0.12 64.25% | |
graham net net | -2.82 - | 2.60 192.06% | -0.51 119.62% | -1.12 120.57% | -3.22 186.31% | 6.39 298.67% | |
graham number | 8.68 - | 13.08 50.80% | 2.26 82.70% | 3.76 66.05% | 9.72 158.60% | 17.70 82.19% | |
income quality | 0.77 - | 0.93 20.44% | 0.45 51.77% | 0.77 71.98% | 0.85 10.12% | 0.86 0.49% | |
intangibles to total assets | 0 - | 0 | 0 | 0 | 0 | 0 | |
interest coverage | 31.87 - | ||||||
interest debt per share | 0.00 - | 0.00 51.43% | -0.03 979.10% | 0.01 127.71% | |||
inventory turnover | |||||||
invested capital | -0.01 - | -0.00 28.31% | -0.00 13.40% | 0.00 132.40% | |||
market cap | 566.63M - | 566.63M 0% | 3.63B 539.75% | 369.90M 89.80% | 430.06M 16.26% | 491.96M 14.39% | |
net current asset value | -26.32M - | 26.24M 199.72% | -20.72M 178.96% | -45.55M 119.82% | -82.37M 80.85% | 240.19M 391.60% | |
net debt to ebitda | 0.65 - | 0.21 67.65% | 14.05 6,567.88% | 4.46 68.27% | 1.95 56.26% | 1.20 38.46% | |
net income per share | -1.20 - | -2.48 106.96% | -0.46 81.46% | -0.60 30.54% | -1.44 138.78% | -2.01 40.23% | |
operating cash flow per share | -0.93 - | -2.32 149.25% | -0.21 91.04% | -0.47 124.34% | -1.22 162.11% | -1.72 41.25% | |
payables turnover | 0.56 - | ||||||
receivables turnover | |||||||
research and ddevelopement to revenue | |||||||
return on tangible assets | -1.47 - | -0.70 52.11% | -0.14 79.49% | -0.22 50.90% | -0.45 107.78% | -0.26 41.90% | |
revenue per share | |||||||
roe | 0.43 - | -0.81 288.35% | 0.93 214.93% | 0.58 38.20% | 0.49 14.74% | -0.29 159.24% | |
roic | 0.41 - | -0.86 311.28% | 0.46 154.01% | 0.58 25.53% | 0.51 12.18% | -0.34 166.37% | |
sales general and administrative to revenue | |||||||
shareholders equity per share | -2.79 - | 3.06 209.88% | -0.49 116.13% | -1.04 111.22% | -2.92 180.07% | 6.92 336.71% | |
stock based compensation to revenue | |||||||
tangible asset value | -26.32M - | 28.92M 209.88% | -20.30M 170.22% | -42.89M 111.22% | -76.83M 79.13% | 245.91M 420.09% | |
tangible book value per share | -2.79 - | 3.06 209.88% | -0.49 116.13% | -1.04 111.22% | -2.92 180.07% | 6.92 336.71% | |
working capital | 5.87M - | 26.43M 349.96% | 129.11M 388.57% | 104.92M 18.74% | 68.04M 35.15% | 240.26M 253.12% |
All numbers in USD (except ratios and percentages)